Frost & Sullivan Technology Innovation Award Conferred on AQTIS Medical BV for its Pioneering Ellanse™

LONDON, Feb. 9, 2011 /PRNewswire/ -- The 2011 Frost & Sullivan European Technology Innovation of the Year Award in Dermal Fillers is presented to AQTIS Medical BV in recognition of its pioneering Ellanse™.

(Logo: http://photos.prnewswire.com/prnh/20081117/FSLOGO)

"This novel range of dermal fillers supports safe and cost-effective treatments in aesthetic medicine and surgery, through immediate and sustained performance, tuneable longevity and total bioresorbability (STAT Technology™)," notes Frost & Sullivan Research Analyst Arjunvasan Ambigapathy. "Aesthetic surgeons have observed positive results from the use of Ellanse™, recommending it for most cosmetic applications."

Ellanse™ comes in four variants (S, M, L, and E) based on the polymer chain strength of poly-caprolactone (PCL), with the duration of action varying from 9 months up to 4 years. PCL, a primary component of Ellanse™, is in the form of smooth microspheres, suspended homogenously in a tailored carboxy-methylcellulose (CMC) gel-carrier and offers optimum viscosity, desired elasticity and uniform homogeneity.

Ellanse™ has been designed to suit a wide range of customer needs - based on the desired duration of action, clients can choose the appropriate Ellanse™ variant. This enables its use across a wide spectrum of treatment procedures.

"Unlike hyaluronic acid (HA) fillers, Ellanse™ offers superior bioresorption, coupled with maximum safety," states Ambigapathy. "Moreover, it delivers results that last twice as long as other leading fillers due to the fact that Ellanse™ acts as a biostimulator, helping patients generate their own new collagen (neocollagenesis). Importantly, during the final stages of bioresorption, the PCL microparticles lose mass and are completely resorbed by intracellular phagocytosis and excreted readily through the metabolic pathway."

Ellanse™ is indicated for a wide array of cosmetic (aesthetic) treatments, which include typical cosmetic thorns like volume-depleted areas and for soft tissue filling around nasolabial folds and marionette lines. The product is also widely used to enhance the zygomatic arch as well as soften wrinkles around the forehead and glabella.

The S, M, L and E strengths of Ellanse™ can be used to treat deep and profound wrinkles. In addition, they can be used to treat intense volumising issues such as lipoatrophy and cosmetic reconstructive surgery, and can also be deployed for hand treatment.

The Technology Innovation Award is presented to the company that has excelled in the following criteria: uniqueness of technology, impact on functionality, impact on customer value and relevance of innovation to industry.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About AQTIS Medical BV

AQTIS Medical BV, the Netherlands is a privately held, medical device company specializing in research & development, manufacturing and commercialisation of innovative injectable medical devices. Ellanse™ dermal filler developed by AQTIS Medical embeds proprietary STAT Technology that consists of a unique set of bioresorbable medical polymer and gel formulations. AQTIS Medical has a distinctive competence in the modification and functionalization of bioresorbable polymers and gels in relation to longevity and other desired performance specifications. Ellanse™ is currently CE approved and used widely in most regions worldwide; In North America FDA approval is expected by the end of 2012.  

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.awards.frost.com.

SOURCE Frost & Sullivan